Completed
PHASE3
INTERVENTIONAL
NCT01415505
Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of nebivolol and valsartan given as a free tablet combination in patient with stage 1 or stage 2 essential hypertension.
Interventions
Name:
Nebivolol, Valsartan and Hydrochlorothiazide
Type:
DRUG
Description:
Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
Primary Outcomes
Measure:
Adverse Event Recording
TimeFrame:
From Baseline to Week 53 (Visit 16)
Description:
Trial Information
NCT ID
NCT01415505
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Forest Laboratories
Last Updated
December 15, 2025